Abstract Details

Title Evaluating the Impact of Levodopa-Induced Dyskinesia and OFF Time in Persons Affected by Parkinson’s Disease: Results of a PMD Alliance Survey

Topic Movement Disorders

Presentation(s) Movement Disorders Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 148

Objective Evaluate the impact of dyskinesia and OFF time on everyday life for persons with Parkinson’s disease (PWPs) and their family members/care partners (CPs).

Background Levodopa is a gold-standard treatment for Parkinson’s disease, but dyskinesia is a common complication of its use, with estimates of up to 90% of PWPs having dyskinesia within 9-15 years of initiating treatment. Many studies evaluating dyskinesia burden are confined to specific clinic populations. The Parkinson and Movement Disorder (PMD) Alliance is a national advocacy organization uniquely positioned to reach across diverse communities of PWPs and CPs to assess impact of dyskinesia and OFF.

Design/Methods PMD Alliance online questionnaire evaluating the presence and impact of dyskinesia and OFF. Questions included basic demographic and disease state information, presence and frequency of dyskinesia or OFF and their impact on social interactions and activities. CPs answered questions relative to their own experiences and those of the PWP.

Results

Preliminary analyses. Of a total 892 surveys, 775 surveys were valid for analysis and came from 527 PWPs (68%) and 248 CPs (32%). Seventy-eight percent (n=604) expressed no or only moderate understanding of dyskinesia and OFF. Fifty-one percent (n=398) reported experiencing dyskinesia and 76% (n=591) reported experiencing OFF at least occasionally, with 48% (n=368) reporting both dyskinesia and OFF. For respondents acknowledging dyskinesia and respondents acknowledging OFF, 86% and 90% reported presence of these problems daily and 61% and 60%, respectively, changed plans and activities to accommodate these.

Of PWPs/CPs reporting dyskinesia and/or OFF (n=621), 32% feel that these motor fluctuations make social interactions difficult, and 27% say that dyskinesia and OFF can be isolating and lead to feelings of loneliness.

Conclusions

Based on PWP and CP surveys, dyskinesia and OFF are common, interrupt daily routine, and are often isolating and impact social interactions.

Authors/Disclosures
Jill M. Farmer, DO, MPH PRESENTER	Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Supernus. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurocrine. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acadia. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal. Dr. Farmer has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Live. The institution of Dr. Farmer has received research support from Parkinson's Foundation.
Mindy K. Bixby, DO (Scripps Clinic Medical Group)	The institution of Dr. Bixby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for USWM. The institution of Dr. Bixby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Adamas. Dr. Bixby has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for USWM. Dr. Bixby has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Adamas .
Salima Brillman, MD	The institution of Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cala Health. The institution of Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acorda. The institution of Dr. Brillman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. The institution of Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. The institution of Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for USWorldMeds. Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Brillman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acorda. Dr. Brillman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal. Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Acadia. Dr. Brillman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Adamas. Dr. Brillman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for USWorld Meds. Dr. Brillman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva.
Sherrie E. Gould, NP (Scripps Clinic Medical Group)	Mrs. Gould has nothing to disclose.
Maria C. Ospina, MD (Regional Parkinson Center/Foothills Neurology)	Dr. Ospina has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Ospina has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for US World Meds. Dr. Ospina has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sunovian. Dr. Ospina has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine. Dr. Ospina has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Ospina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kywoa Kirin. Dr. Ospina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Adamas. Dr. Ospina has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Ospina has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurocrine. Dr. Ospina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovian. Dr. Ospina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Acorda. Dr. Ospina has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amneal. Dr. Ospina has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Ospina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for US World Meds.
	No disclosure on file
Judy Lytle	Judy Lytle has received personal compensation for serving as an employee of Adamas Pharmaceuticals, Inc. Judy Lytle has received stock or an ownership interest from Adamas Pharmaceuticals, Inc.

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details